ISIS Neutron and Muon Source Data Journal

Paclitaxel delivery using lipid-based nanostructured drug carriers

Abstract: Cancer is one of the leading causes of mortality worldwide, accounting for one in six deaths. This disease affects individuals of all ages and ethnic backgrounds, presenting a significant challenge to global public health. The main challenges in breast cancer (BC) chemotherapy are related to drug resistance, especially in the case of triple-negative BC. Nanotechnology strategies can improve the efficacy of chemotherapy by promoting sustained release and reducing systemic toxicity through drug delivery systems (DDS).This project aims to characterize, using Small Angle Neutron Scattering (SANS), nanostructured lipid carriers (NLC) containing ?-caryophyllene (BCP) as a functional excipient (with anticancer and analgesic effects) and the taxane paclitaxel (PTX) as an experimental co-administration strategy to increase the bioavailability and reduce the toxicity of PTX. This study will contribute to the development of a new pharmaceutical formulation based on nanotechnology that is more effective and less toxic than commercially available PTX formulations, with the aim of improving the prognosis and quality of life of patients with BC.

Principal Investigator: Dr Margareth K.K.D. Franco
Experimenter: Dr Fabiano Yokaichiya
Local Contact: Dr Leide Cavalcanti
Experimenter: Mr Marcio Bulla
Experimenter: Mr Rodrigo Rhinow

DOI: 10.5286/ISIS.E.RB2420182

ISIS Experiment Number: RB2420182

Publisher: STFC ISIS Neutron and Muon Source

Data format: RAW/Nexus
Select the data format above to find out more about it.

Data Citation

The recommended format for citing this dataset in a research publication is as:
[author], [date], [title], [publisher], [doi]

For Example:
Dr Margareth K.K.D. Franco et al; (2025): Paclitaxel delivery using lipid-based nanostructured drug carriers, STFC ISIS Neutron and Muon Source, https://doi.org/10.5286/ISIS.E.RB2420182

Data is released under the CC-BY-4.0 license.